Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Supernus Pharmaceuticals Inc. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 1 distinct art unit, indicating a concentrated focus on a pharmaceutical sub-sector. However, the company is dealing with 2 distinct examiners, meaning that even within the same art unit, the prosecution strategy must account for different individual perspectives on patentability. This split requires the applicant to be prepared for varying levels of scrutiny regarding pharmaceutical claims.
The busiest examiner for the portfolio is YOO, SUN JAE, who is responsible for 1 pending office action. With pending office actions in total, the workload is split among the distinct examiners. This arrangement requires the applicant to maintain consistent arguments across the art unit while addressing the specific feedback provided by each examiner in the Biotechnology & Pharmaceuticals space. The presence of YOO, SUN JAE within the art unit highlights the importance of understanding individual examiner behavior.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18899299 | SUBSTITUTED DERIVATIVES OF ISOINDOLES AND USES THEREOF | YOUNGBLOOD, WILLIAM JUSTIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18899299 | SUBSTITUTED DERIVATIVES OF ISOINDOLES AND USES THEREOF | YOUNGBLOOD, WILLIAM JUSTIN | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18999866 | DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF | YOO, SUN JAE | 1621 | §112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18899299 | SUBSTITUTED DERIVATIVES OF ISOINDOLES AND USES THEREOF | YOUNGBLOOD, WILLIAM JUSTIN | — | §101§102§112DP | Non-Final OA | — | Pending | Sep 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial